HRP20170840T1 - Supstituirani ksantini i metode njihove uporabe - Google Patents

Supstituirani ksantini i metode njihove uporabe

Info

Publication number
HRP20170840T1
HRP20170840T1 HRP20170840TT HRP20170840T HRP20170840T1 HR P20170840 T1 HRP20170840 T1 HR P20170840T1 HR P20170840T T HRP20170840T T HR P20170840TT HR P20170840 T HRP20170840 T HR P20170840T HR P20170840 T1 HRP20170840 T1 HR P20170840T1
Authority
HR
Croatia
Prior art keywords
methods
substituted xanthines
xanthines
substituted
Prior art date
Application number
HRP20170840TT
Other languages
English (en)
Inventor
Bertrand Chenard
Randall Gallaschun
Original Assignee
Hydra Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50680155&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20170840(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hydra Biosciences, Inc. filed Critical Hydra Biosciences, Inc.
Publication of HRP20170840T1 publication Critical patent/HRP20170840T1/hr
Publication of HRP20170840T4 publication Critical patent/HRP20170840T4/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
HRP20170840TT 2013-03-15 2017-06-01 Supstituirani ksantini i metode njihove uporabe HRP20170840T4 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361789724P 2013-03-15 2013-03-15
EP14722452.1A EP2970303B3 (en) 2013-03-15 2014-03-14 Substituted xanthines and methods of use thereof
PCT/US2014/027920 WO2014143799A2 (en) 2013-03-15 2014-03-14 Substituted xanthines and methods of use thereof

Publications (2)

Publication Number Publication Date
HRP20170840T1 true HRP20170840T1 (hr) 2017-09-08
HRP20170840T4 HRP20170840T4 (hr) 2018-11-16

Family

ID=50680155

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20170840TT HRP20170840T4 (hr) 2013-03-15 2017-06-01 Supstituirani ksantini i metode njihove uporabe

Country Status (32)

Country Link
US (6) US9359359B2 (hr)
EP (1) EP2970303B3 (hr)
JP (1) JP6360149B2 (hr)
KR (1) KR102227629B1 (hr)
CN (2) CN107082782B (hr)
AU (1) AU2014228206C1 (hr)
CA (1) CA2899646C (hr)
CL (1) CL2015002738A1 (hr)
CY (1) CY1119042T1 (hr)
DK (1) DK2970303T6 (hr)
EA (1) EA028815B1 (hr)
ES (1) ES2636835T7 (hr)
HK (1) HK1217329A1 (hr)
HR (1) HRP20170840T4 (hr)
HU (1) HUE033528T4 (hr)
IL (1) IL240216B (hr)
LT (1) LT2970303T (hr)
MX (1) MX370372B (hr)
MY (1) MY189912A (hr)
NZ (1) NZ711718A (hr)
PE (1) PE20151779A1 (hr)
PH (1) PH12015502141B1 (hr)
PL (1) PL2970303T6 (hr)
PT (1) PT2970303T (hr)
RS (1) RS56066B2 (hr)
SG (1) SG11201506479TA (hr)
SI (1) SI2970303T1 (hr)
TW (1) TWI609867B (hr)
UA (1) UA117470C2 (hr)
UY (1) UY35488A (hr)
WO (1) WO2014143799A2 (hr)
ZA (1) ZA201505414B (hr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173750B2 (en) 2009-04-23 2012-05-08 ATRP Solutions, Inc. Star macromolecules for personal and home care
US9359359B2 (en) 2013-03-15 2016-06-07 Hydra Biosciences, Inc. Substituted xanthines and methods of use thereof
WO2016023831A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives
CA2989161C (en) 2015-03-27 2022-03-01 Latvian Institute Of Organic Synthesis Ethynylxanthines, preparation and use for cancer treatment
WO2016159746A1 (en) 2015-03-27 2016-10-06 Latvian Institute Of Organic Synthesis Novel ethynylxanthines, their preparation and use as inhibitors of matrix metalloproteinases and angiogenesis
GB2553686B (en) 2015-03-27 2020-06-03 Latvian Inst Organic Synthesis Ethynylxanthines, preparation and use as calcium ion channel modulators
PT3280417T (pt) * 2015-04-08 2020-10-30 Lewis And Clark Pharmaceuticals Inc Carbamatos de alquinilo substituídos com xantina/carbamatos reversos utilizados como antagonistas de adenosina a2b
CN107118586A (zh) * 2016-02-24 2017-09-01 中国科学技术大学 含氮杂环基取代的烯类化合物的用途
GB201702160D0 (en) * 2017-02-09 2017-03-29 Univ Leeds Innovations Ltd Inhibitors for use in therapy
US11666577B2 (en) * 2017-02-28 2023-06-06 National Institute Of Biological Sciences, Beijing MLKL inhibitors
WO2018157800A1 (en) * 2017-02-28 2018-09-07 National Institute Of Biological Sciences, Beijing Mlkl inhibitors
CN110997675B (zh) * 2017-07-11 2022-06-07 勃林格殷格翰国际公司 新的取代的黄嘌呤衍生物
EP3761989A4 (en) * 2018-03-05 2021-11-24 Goldfinch Bio, Inc. IMIDAZODIAZEPINEDIONES AND THEIR METHODS FOR USE
JP7408662B2 (ja) 2018-12-12 2024-01-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換キサンタン誘導体
CN113166151B (zh) 2018-12-12 2023-12-01 勃林格殷格翰国际有限公司 经取代的黄嘌呤衍生物
CN112979651B (zh) * 2021-04-09 2022-02-01 南京纽邦生物科技有限公司 一种副黄嘌呤的制备方法
CN113354646B (zh) * 2021-07-06 2022-11-15 南开大学 8-芳氧基烷氧基取代黄嘌呤衍生物及其制备方法和应用
CN115636831A (zh) * 2022-10-27 2023-01-24 中国药科大学 稠合嘧啶二酮类化合物、其用途以及药物组合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4304650A1 (de) * 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US6878715B1 (en) * 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
JP4191269B2 (ja) 1996-05-17 2008-12-03 興和株式会社 新規なアニリド化合物及びこれを含有する医薬
JPH10318487A (ja) 1997-05-16 1998-12-04 Mitsubishi Gas Chem Co Inc 真空断熱材用ゲッタ
US6075029A (en) 1998-01-02 2000-06-13 Cell Therapeutics, Inc. Xanthine modulators of metabolism of cellular P-450
US6187780B1 (en) * 1998-04-16 2001-02-13 Boehringer Ingelheim Pharma Kg Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
EP1171442B1 (en) * 1999-04-09 2005-12-07 Cell Therapeutics, Inc. Xanthine derivatives and analogs as cell signalling inhibitors
EP1561752A1 (en) * 2000-07-04 2005-08-10 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
AU3950802A (en) 2000-12-07 2002-06-18 Cv Therapeutics Inc Abca-1 elevating compounds
PT1368349E (pt) * 2001-02-24 2007-04-30 Boehringer Ingelheim Pharma Derivados de xantina, sua preparação e sua utilização como medicamento
NZ532816A (en) * 2001-11-09 2005-11-25 Cv Therapeutics Inc A2B adenosine receptor antagonists
DK1622908T3 (da) * 2003-05-06 2008-11-17 Cv Therapeutics Inc Xanthin-derivater som A2B adenosin-receptor-antagonister
CA2545944A1 (en) 2003-11-13 2005-06-02 Board Of Regents, The University Of Texas System Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure
EP1841448A2 (en) 2004-12-30 2007-10-10 Diakine Therapeutics, Inc. Pharmaceutical compositions and methods for restoring beta-cell mass and function
WO2006089168A2 (en) 2005-02-18 2006-08-24 Cornell Research Foundation, Inc. Methods for modulating ion channels
JP2009504592A (ja) * 2005-08-10 2009-02-05 スミスクライン・ビーチャム・コーポレイション 選択的ｈｍ７４ａアゴニストとしてのキサンチン誘導体
US20080214563A1 (en) 2005-09-06 2008-09-04 Mui Cheung Benzimidazole Thiophene Compounds As Plk Modulators
WO2007065595A2 (en) * 2005-12-07 2007-06-14 Ucb Pharma, S.A. Xanthine derivatives, processes for preparing them and their uses
CA2634152A1 (en) * 2005-12-22 2007-06-28 Hydra Biosciences, Inc. Trpa1 inhibitors for treating pain
CN101405000A (zh) 2006-01-19 2009-04-08 艾博特公司 2-亚胺基-苯并咪唑化合物
WO2007101213A2 (en) 2006-02-28 2007-09-07 Kalypsys, Inc. Novel 2-oxo-1,2,3,4-tetrahydropyrimidines, bicyclic pyrimidine diones and imidazolidine-2,4-diones useful as inducible nitric oxide synthase inhibitors
US20090269313A1 (en) * 2006-07-19 2009-10-29 Diakine Therapeutics, Inc. Encapsulation system
WO2009157938A1 (en) * 2008-06-26 2009-12-30 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for treating cancer
EP2467398B1 (en) 2009-08-20 2019-10-09 Poseida Therapeutics, Inc. Trpc4 inhibitors and uses thereof
WO2011114184A1 (en) 2010-03-15 2011-09-22 Glenmark Pharmaceuticals S.A. Amides of heterocyclic compounds as trpa1 inhibitors
US9260430B2 (en) 2010-06-08 2016-02-16 Hydra Biosciences, Inc. Use of TRPA1 antagonists to prevent or treat infections caused by biological-warfare agents
JP2013023102A (ja) 2011-07-22 2013-02-04 Panasonic Corp 列車情報提供システム
JP2014521724A (ja) * 2011-08-09 2014-08-28 ハイドラ バイオサイエンシズ インコーポレイテッド 一過性受容器電位イオンチャネルｔｒｐａ１の阻害
CN103121970B (zh) 2012-12-04 2015-04-29 中国科学院昆明植物研究所 苯并咪唑及其衍生物，其药物组合物及其在制备抗抑郁药物中的应用
US9359359B2 (en) 2013-03-15 2016-06-07 Hydra Biosciences, Inc. Substituted xanthines and methods of use thereof

Also Published As

Publication number Publication date
AU2014228206B2 (en) 2018-05-10
PH12015502141A1 (en) 2016-01-25
CN105143229A (zh) 2015-12-09
KR102227629B1 (ko) 2021-03-16
PH12015502141B1 (en) 2016-01-25
JP6360149B2 (ja) 2018-07-18
MX370372B (es) 2019-12-11
EP2970303B9 (en) 2017-09-20
RS56066B2 (sr) 2018-09-28
LT2970303T (lt) 2017-07-25
UY35488A (es) 2014-10-31
US20180244674A1 (en) 2018-08-30
US20190322667A1 (en) 2019-10-24
BR112015021164A8 (pt) 2019-12-03
US11958854B2 (en) 2024-04-16
IL240216B (en) 2018-11-29
HK1217329A1 (zh) 2017-01-06
AU2014228206C1 (en) 2018-10-25
CY1119042T1 (el) 2018-01-10
HUE033528T2 (hu) 2017-12-28
CA2899646A1 (en) 2014-09-18
PE20151779A1 (es) 2015-11-20
US10399982B2 (en) 2019-09-03
ZA201505414B (en) 2016-03-30
SG11201506479TA (en) 2015-09-29
EP2970303B1 (en) 2017-05-10
MX2015011617A (es) 2016-04-25
JP2016513717A (ja) 2016-05-16
NZ711718A (en) 2020-05-29
EP2970303A2 (en) 2016-01-20
CA2899646C (en) 2021-08-31
US20230040259A1 (en) 2023-02-09
WO2014143799A2 (en) 2014-09-18
CL2015002738A1 (es) 2016-06-10
PL2970303T3 (pl) 2017-08-31
WO2014143799A9 (en) 2014-12-24
SI2970303T1 (sl) 2017-08-31
HUE033528T4 (en) 2018-05-02
US11208409B2 (en) 2021-12-28
CN107082782B (zh) 2020-03-20
TWI609867B (zh) 2018-01-01
EA028815B1 (ru) 2018-01-31
DK2970303T3 (en) 2017-06-26
CN105143229B (zh) 2017-06-30
US20140275071A1 (en) 2014-09-18
IL240216A0 (en) 2015-09-24
ES2636835T7 (es) 2018-11-20
EP2970303B3 (en) 2018-08-01
US9359359B2 (en) 2016-06-07
US20170305910A1 (en) 2017-10-26
ES2636835T3 (es) 2017-10-09
WO2014143799A4 (en) 2015-02-12
WO2014143799A3 (en) 2014-11-06
RS56066B1 (sr) 2017-10-31
DK2970303T5 (en) 2018-01-02
MY189912A (en) 2022-03-21
KR20150133233A (ko) 2015-11-27
DK2970303T6 (en) 2018-10-08
UA117470C2 (uk) 2018-08-10
US20160237089A1 (en) 2016-08-18
AU2014228206A1 (en) 2015-09-24
EA201591615A1 (ru) 2016-05-31
US9969736B2 (en) 2018-05-15
CN107082782A (zh) 2017-08-22
PT2970303T (pt) 2017-06-23
PL2970303T6 (pl) 2018-12-31
HRP20170840T4 (hr) 2018-11-16
TW201533044A (zh) 2015-09-01
BR112015021164A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
HRP20170840T1 (hr) Supstituirani ksantini i metode njihove uporabe
IL290547A (en) Antibodies and methods of use
IL244495A0 (en) Anti-alpha-synuclein antibodies and methods of use
GB2535360B (en) Methods of preparing polyhemiaminals and polyhexahydrotriazines
SG11201600707QA (en) Substituted aminopyrimidine compounds and methods of use
HK1225612A1 (zh) 抗ly6e抗體及使用方法
HK1224307A1 (zh) 原毒素- 變體及其使用方法
HK1218247A1 (zh) 益生菌和使用方法
IL245272A0 (en) pif-transfected cells and methods of use